Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals

Por Clelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, Stelly Ballet, Anne Vincent-Salomon, Perrine Vuagnat, Audrey Bellesoeur, Jean-Yves Pierga, Marc-Henri Stern, Francois-Clement Bidard, Florence Lerebours
Publicado em 2022-04-01

Kindlin‐1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types

Por Paula Azorin, Florian Bonin, Zakia Tariq, Ambre Petitalot, Florence Coussy, Elisabetta Marangoni, Veronique Becette, Yves Denoux, Anne Vincent‐Salomon, Christophe Le Tourneau, Linda Larbi Cherif, Jerzy Klijanienko, Maud Kamal, Ivan Bièche, Rosette Lidereau, Keltouma Driouch
Publicado em 2022-04-01

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

Por Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Marco Silvestri, José Baselga, Martine Piccart, Jens Huober, Miguel Izquierdo, Lorena de la Pena, Florentine S. Hilbers, Evandro de Azambuja, Michael Untch, Lajos Pusztai, Kathleen Pritchard, Paolo Nuciforo, Anne Vincent-Salomon, Fraser Symmans, Giovanni Apolone, Filippo G. de Braud, Marilena V. Iorio, Paolo Verderio, Maria Grazia Daidone
Publicado em 2020-02-01